Discussions with leaders: Janet Eary, MD, from the Cancer Imaging Program at the National Cancer Institute, talks with Lale Kostakoglu, MD, MPH, about advancing imaging innovation at the national level.
Page 667
Amyloid PET workshop: Jagust and other participants summarize the presentations and findings of an expert workshop on the role of quantitative brain amyloid PET imaging in staging, prognosis, and longitudinal assessment of Alzheimer disease.
Page 670
Managing advanced prostate cancer: Viscuse and colleagues provide an educational overview of challenges in sequencing therapies for metastatic castration-resistant prostate cancer and highlight the evolving role of 177Lu-PSMA-617.
Page 679
Is 161Tb really happening? Kong and colleagues offer perspective on potential advantages of 161Tb as an alternative therapeutic radiation emitter and review preclinical, clinical, and safety studies, as well as production and scalability issues.
Page 686
[18F]FET PET/MRI for pituitary tumors: Pruis and colleagues assess the diagnostic yield of this multimodal technique for detection of small functional pituitary tumors in patients in whom the source of excess hormone production remains unidentified or uncertain.
Page 688
131I therapy and cancer risk: Kim and colleagues investigate in a large-cohort study whether the risk of cancer is greater in patients with Graves disease who receive radioiodine therapy than in those who do not.
Page 693
HER2 PET in HER2-low breast cancer: Altena and colleagues report on a pilot study of the feasibility and safety of HER2-specific PET imaging with [68Ga]Ga-ABY-025 for visualization of HER2-low metastatic breast cancer.
Page 700
Optimal PET/CT cutoff in PHERGain trial: Gebhart and colleagues describe the best cutoff of SUVmax reduction for pathologic complete response prediction in this trial evaluating the potential of metabolic imaging to identify breast cancer candidates for chemotherapy deescalation.
Page 708
Dual-blood input and lung tumors: Wang and colleagues model the dual-blood input function and study its impact on kinetic quantification of normal lung tissue and lung tumors using high-temporal-resolution dynamic PET imaging.
Page 714
PD-L1 PET in gastroesophageal cancer: Cytryn and colleagues detail the results of a pilot study of the safety and feasibility of PET imaging with 18F-BMS-986229, a programmed death ligand 1–targeting radiotracer, in patients with gastroesophageal cancer.
Page 722
Gal-1 PET and ICB therapy: Liu and colleagues explore in mouse models the promise of galectin-1–targeted PET for early-stage monitoring of tumor responses to immune checkpoint blockade therapy and note additional results in enhanced immunotherapy efficacy.
Page 728
PSMA RLT clinical experience: Moradi Tuchayi and colleagues share real-world experience with 177Lu-PSMA-617 radioligand therapy, including pretreatment PSMA PET, laboratory findings, overall survival, toxicities, and changes in prostate-specific antigen.
Page 735
[68Ga]Ga-DPI-4452 in ccRCC: Hofman and colleagues report on first-in-humans PET imaging characteristics, pharmacokinetics, and safety with this carbonic anhydrase IX–binding radiolabeled peptide in clear cell renal cell carcinoma.
Page 740
Modern molecular imaging in RCC: Grünwald and colleagues offer commentary on an article in this issue of JNM on development of a novel potential theranostic tracer in renal cell carcinoma, including historical perspectives, current challenges, and future promise.
Page 744
Retreatment with 177Lu-DOTATATE: Delpassand and colleagues evaluate the effectiveness and safety of additional cycles of 177Lu-DOTATATE therapy in patients with progressive neuroendocrine tumors.
Page 746
Red marrow dose and hematologic toxicity: Blakkisrud and colleagues investigate associations between Monte Carlo–derived absorbed dose to red marrow and hematologic toxicity in patients being treated with [177Lu]Lu-DOTATATE for neuroendocrine tumors.
Page 753
Preclinical characterization of DPI-4452: Massière and colleagues evaluate protein carbonic anhydrase IX expression in multiple tumor types and provide in vitro and in vivo evaluations of 68Ga-labeled and 177Lu-labeled DPI-4452 for theranostic applications.
Page 761
AI and heart failure admissions: Feher and colleagues use artificial intelligence models incorporating clinical, stress test, and imaging parameters to predict hospitalization for acute heart failure exacerbation in patients undergoing SPECT/CT myocardial perfusion imaging.
Page 768
CD163 PET and atherosclerosis: Zhang and colleagues develop a targeted PET radiotracer for imaging CD163-positive macrophages in multiple mouse atherosclerosis models and assess the potential of CD163 as a biomarker for atherosclerosis in humans.
Page 775
PET reconstruction in Aβ quantitation: Ruwanpathirana and colleagues examine the impact of spatial resolution on amyloid-β PET quantitation in cross-sectional and longitudinal data, with implications for understanding Alzheimer disease progression and the role of PET imaging in early-stage management.
Page 781
11C ligands for PDE4D: Jiang and colleagues detail robust PET 11C-radioligand quantification of phosphodiesterase-4D, a target for treating neuropsychiatric disorders, in monkey brain and discuss the potential for clinical use.
Page 788
MIRD Pamphlet No. 29: Marquis and members of the MIRD initiative describe development, validation, and application of an activity/absorbed dose calculation worksheet to support selective internal radiation treatment dosimetry calculations as part of the MIRDsoft.org suite of research dosimetry tools.
Page 794
PET normalization methods for radiomics: Haider and colleagues investigate the effects of 18F-FDG PET voxel intensity normalization on radiomic features of oropharyngeal squamous cell carcinoma and machine learning–generated radiomic biomarkers.
Page 803
In silico imaging trial in α-particle therapy: Li and colleagues perform an in silico trial to assess the potential of projection-domain low-count quantitative SPECT in 223Ra therapy, mirroring patient and imaging system variabilities.
Page 810
PSMA dual-time-point imaging: Unterrainer and colleagues present illustrated commentary on their institutional experience with dual-time-point standard whole-body and additional short-interval late postvoid pelvic [68Ga]Ga-PSMA-11 imaging in prostate cancer lesion detection and characterization.
Page 818
FAPI PET in borderline ovarian tumor: Unterrainer and colleagues offer a case study indicating the potential for [68Ga]Ga-fibroblast activation protein inhibitor-46 PET in differentiating malignant from borderline ovarian tumors.
Page 820
- © 2024 by the Society of Nuclear Medicine and Molecular Imaging.
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.